Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Uganda’s HIV criminalization, mandatory testing bill signed into law against local and international cautions of harms to health, human rights
Jail terms to punish “attempted” and “intentional” transmission of HIV, as well as forced HIV testing of sex crime victims, people accused of sex crimes, pregnant […]
Xpert use reduced wait for treatment, study shows, but health system, patient challenges remain barriers to full benefits
The demand for, and the promise of, quick accurate tools to diagnose tuberculosis, and to discover resistance to basic TB treatments, are based on a simple […]
Along with maintaining funding for fighting global tuberculosis, the United States government must better coordinate with the most affected countries on TB research and development, said […]
PEPFAR’s South Africa “transition”: Nearly 20 percent of patients went unaccounted for when care was transferred, study finds
Survey finding gaps in care, records during transfer of patients from PEPFAR-supported program to community-based clinics comes as new report cites need for data The patients […]